Skip to main content
Clinical Trials/NCT02551198
NCT02551198
Completed
Phase 3

Comparative Evaluation the Efficacy of 2L Polyethylene Glycol With Ascorbic Acid (PEG-Asc) and Oral Sulfate Solution (OSS) in Split Method for Bowel Preparation (The Phase III Prospective Randomized Clinical Trial)

National Cancer Center, Korea1 site in 1 country184 target enrollmentNovember 1, 2015
ConditionsHealthy
InterventionsHAPREP®SUCLEAR®

Overview

Phase
Phase 3
Intervention
HAPREP®
Conditions
Healthy
Sponsor
National Cancer Center, Korea
Enrollment
184
Locations
1
Primary Endpoint
Adequacy of bowel preparation
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Colonoscopy is considered by many the preferred mode of screening for colorectal cancer (CRC). The effectiveness of any CRC screening program is critically dependent on an adequate bowel preparation.

For bowel preparation, effective, well-tolerated and safe methods should be applied.

Recently, oral sulfate solution was adopted to Korea. Still, in Korea, there was no data of direct comparison of 2L polyethylene glycol with ascorbic acid (PEG-Asc) and oral sulfate solution (OSS) in split method for bowel preparation. Therefore, in this study, we planned the comparative evaluation the efficacy of PEG-Asc and OSS in split method for bowel preparation

Detailed Description

For direct comparison of 2L polyethylene glycol with ascorbic acid (PEG-Asc) and oral sulfate solution (OSS) in split method for bowel preparation

Registry
clinicaltrials.gov
Start Date
November 1, 2015
End Date
September 1, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dae Kyung Sohn

M.D., PhD

National Cancer Center, Korea

Eligibility Criteria

Inclusion Criteria

  • Age, between 20 and 75
  • Patients who were visited the outpatient clinic for National Cancer Cancer or Daehang hospital to undergo colonoscopy

Exclusion Criteria

  • Gastrointestinal obstruction
  • Bowel perforation
  • Gastric retention
  • Toxic colitis or toxic megacolon
  • Known allergies to components of the OSS and PEG-Asc
  • History of colorectal resection
  • History of abdominopelvic surgery within 6 months
  • uncontrolled electrolyte imbalance
  • hereditary Phenylketonuria
  • Severe dehydration status

Arms & Interventions

HAPREP® (PEG-Asc)

subjects randomized to 2L polyethylene glycol with ascorbic acid (PEG-Asc) were instructed to use PEG-Asc for bowel preparation : PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]

Intervention: HAPREP®

SUCLEAR® (OSS)

subjects randomized to oral sulfate solution were instructed to use oral sulfate solution (OSS) for bowel preparation : OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]

Intervention: SUCLEAR®

Outcomes

Primary Outcomes

Adequacy of bowel preparation

Time Frame: on the day of colonoscopy

Secondary Outcomes

  • adenoma detection rate(whithin 3 weeks from the day of colonoscopy)
  • 5-point scale symptom questionnaire for drug tolerability(on the day of colonoscopy)
  • Number of Participants with Adverse Events(on the day of colonoscopy)
  • colonoscopy insertion time(on the day of colonoscopy)

Study Sites (1)

Loading locations...

Similar Trials